The Importance of Early Intervention in Prefibrotic Disease Treatment

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in anemia and thrombocytopenia. There are many unmet treatment needs that remain in this space.

This week’s podcast features a discussion from the International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS / iwMPN 2024) held in Boston, MA. You will hear from Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Abdulraheem Yacoub, MD, The University of Kansas, Westwood, KS, Aaron Gerds, MD, MS, Cleveland Clinic, Cleveland, OH, and Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, who discuss unmet treatment needs in MF. They focus on the management of prefibrotic MF and thrombocytopenia, novel agents beyond the JAK/STAT pathway, and endpoints for clinical trials.

The post Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials appeared first on VJHemOnc.